OPK

OPKO HealthNasdaqGS:OPK Stock Report

Market Cap

US$2.6b

7D

1.6%

1Y

24.6%

Updated

22 Sep, 2021

Data

Company Financials +
OPK fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance3/6
Financial Health5/6
Dividends0/6

OPK Overview

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.

OPKO Health Competitors

Price History & Performance

Summary of all time highs, changes and price drops for OPKO Health
Historical stock prices
Current Share PriceUS$3.80
52 Week HighUS$3.02
52 Week LowUS$6.27
Beta1.76
1 Month Change-1.55%
3 Month Change0.80%
1 Year Change24.59%
3 Year Change2.15%
5 Year Change-65.04%
Change since IPO-15.56%

Recent News & Updates

Shareholder Returns

OPKUS BiotechsUS Market
7D1.6%-0.9%-1.7%
1Y24.6%28.4%36.2%

Return vs Industry: OPK underperformed the US Biotechs industry which returned 26.1% over the past year.

Return vs Market: OPK underperformed the US Market which returned 31.5% over the past year.

Price Volatility

Is OPK's price volatile compared to industry and market?
OPK volatility
OPK Beta1.76
Industry Beta1.03
Market Beta1

Stable Share Price: OPK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: OPK's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19915,269Phil Frosthttps://www.opko.com

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units, as well as 4Kscore prostate cancer testing services. The company’s Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins.

OPKO Health Fundamentals Summary

How do OPKO Health's earnings and revenue compare to its market cap?
OPK fundamental statistics
Market CapUS$2.59b
Earnings (TTM)US$70.91m
Revenue (TTM)US$1.91b

36.5x

P/E Ratio

1.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OPK income statement (TTM)
RevenueUS$1.91b
Cost of RevenueUS$1.25b
Gross ProfitUS$662.40m
ExpensesUS$591.49m
EarningsUS$70.91m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.11
Gross Margin34.67%
Net Profit Margin3.71%
Debt/Equity Ratio11.8%

How did OPK perform over the long term?

See historical performance and comparison

Valuation

Is OPKO Health undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: OPK ($3.8) is trading below our estimate of fair value ($18.27)

Significantly Below Fair Value: OPK is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: OPK is poor value based on its PE Ratio (36.5x) compared to the US Biotechs industry average (25.2x).

PE vs Market: OPK is poor value based on its PE Ratio (36.5x) compared to the US market (17.5x).


Price to Earnings Growth Ratio

PEG Ratio: OPK is good value based on its PEG Ratio (0.6x)


Price to Book Ratio

PB vs Industry: OPK is good value based on its PB Ratio (1.5x) compared to the US Biotechs industry average (3.2x).


Future Growth

How is OPKO Health forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

58.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OPK's forecast earnings growth (58.1% per year) is above the savings rate (2%).

Earnings vs Market: OPK's earnings (58.1% per year) are forecast to grow faster than the US market (14.9% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: OPK's revenue is expected to decline over the next 3 years (-1.4% per year).

High Growth Revenue: OPK's revenue is forecast to decline over the next 3 years (-1.4% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OPK's Return on Equity is forecast to be high in 3 years time


Past Performance

How has OPKO Health performed over the past 5 years?

-2.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OPK has high quality earnings.

Growing Profit Margin: OPK became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: OPK has become profitable over the past 5 years, growing earnings by -2% per year.

Accelerating Growth: OPK has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: OPK has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: OPK's Return on Equity (4.1%) is considered low.


Financial Health

How is OPKO Health's financial position?


Financial Position Analysis

Short Term Liabilities: OPK's short term assets ($547.0M) exceed its short term liabilities ($304.0M).

Long Term Liabilities: OPK's short term assets ($547.0M) exceed its long term liabilities ($375.1M).


Debt to Equity History and Analysis

Debt Level: OPK's debt to equity ratio (11.8%) is considered satisfactory.

Reducing Debt: OPK's debt to equity ratio has increased from 4.7% to 11.8% over the past 5 years.

Debt Coverage: OPK's debt is well covered by operating cash flow (52.6%).

Interest Coverage: OPK's interest payments on its debt are well covered by EBIT (5.2x coverage).


Balance Sheet


Dividend

What is OPKO Health current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OPK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OPK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OPK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OPK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OPK's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.2yrs

Average management tenure


CEO

Phil Frost (85 yo)

14.5yrs

Tenure

US$1,538,200

Compensation

Dr. Phillip Frost, also known as Phil, M.D., Ph D., has been the Chairman, Chief Executive Officer and Director of OPKO Health, Inc. since March 27, 2007. Dr. Frost serves as the Managing Director and Gene...


CEO Compensation Analysis

Compensation vs Market: Phil's total compensation ($USD1.54M) is below average for companies of similar size in the US market ($USD5.34M).

Compensation vs Earnings: Phil's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: OPK's management team is seasoned and experienced (8.2 years average tenure).


Board Members

Experienced Board: OPK's board of directors are seasoned and experienced ( 14.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: OPK insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

OPKO Health, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: OPKO Health, Inc.
  • Ticker: OPK
  • Exchange: NasdaqGS
  • Founded: 1991
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.588b
  • Shares outstanding: 681.16m
  • Website: https://www.opko.com

Number of Employees


Location

  • OPKO Health, Inc.
  • 4400 Biscayne Boulevard
  • Miami
  • Florida
  • 33137
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/22 22:40
End of Day Share Price2021/09/22 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.